Company profile
ACTUATE THERAPEUTICS, INC.
NASDAQ:ACTUBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ELRAGLUSIB | phase2 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04832438 | phase2 | withdrawn | 2030-12-18 | 2033-06-18 | Actuate Therapeutics Inc. | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma |
| NCT03678883 | phase2 | active_not_recruiting | 2019-01-04 | 2026-06-01 | Actuate Therapeutics Inc. | 9-ING-41 in Patients With Advanced Cancers |
| NCT04239092 | phase1 | terminated | 2020-06-05 | 2025-07-07 | Actuate Therapeutics Inc. | 9-ING-41 in Pediatric Patients With Refractory Malignancies. |
| NCT04218071 | phase2 | completed | 2020-08-20 | 2022-10-13 | Actuate Therapeutics Inc. | Actuate 1901: 9-ING-41 in Myelofibrosis |
| NCT07714395 | phase1_2 | not_yet_recruiting | 2026-10-01 | 2029-07-01 | Actuate Therapeutics Inc. | Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors |
FDA applications (0)
No records yet.